MCID: PRS042
MIFTS: 40

Prostate Disease

Categories: Nephrological diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Prostate Disease

Summaries for Prostate Disease

MedlinePlus: 41 What is the prostate? The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen. What are prostate diseases? There are many types of prostate diseases: Prostatitis is inflammation (swelling and pain) in the prostate gland. It's the most common type of prostate problem in people under than age 50. There are different types: Chronic prostatitis is also called chronic pelvic pain syndrome. It's the most common type of prostatitis. Acute bacterial prostatitis starts suddenly from a bacterial infection and is treated with antibiotics. It is not common. Chronic bacterial prostatitis happens when a bacterial infection keeps coming back. The symptoms usually start slowly. It may take longer to treat than acute bacterial prostatitis. Asymptomatic prostatitis has no symptoms and usually doesn't need treatment. You may learn you have it after having tests for other health problems. Enlarged prostate is also called benign prostatic hyperplasia (BPH). The prostate gland tends to grow larger with age. That's why enlarged prostate is very common in older people and rare in those who are under age 40. When the prostate grows larger, it may press on your urethra and cause problems with urination. Prostate cancer happens when cancer cells form in the prostate gland. Prostate cancer is a common type of cancer in those aged 50 and older. Most prostate cancers grow slowly and may never cause health problems. But certain prostate cancers are serious. Who is more likely to develop prostate diseases? Anyone with a prostate can develop prostate problems. But some people are at higher risk. You may be more likely to develop prostatitis if you have: A lower urinary tract infection, also called a UTI. An infection in your lower urinary tract (bladder and urethra) may lead to acute or chronic bacterial prostatitis. Nerve damage in your lower urinary tract from surgery or an injury. This may lead to chronic prostatitis. Emotional stress, which can lead to chronic prostatitis. You may be more likely to develop an enlarged prostate (BPH) if you: Are age 40 or older. Have family members who have had BPH. Have certain health conditions such as: Obesity. Heart disease and problems with blood circulation. Type 2 diabetes. Don't get enough physical activity. You may be more likely to develop prostate cancer if you: Are older than age 50. Have a parent, sibling, or child who has or had prostate cancer. Are African American. What are the symptoms of prostate diseases? The symptoms of prostate problems include: Needing to urinate a lot. Needing to rush to the bathroom, but not being able to urinate or only going a little. Leaking or dribbling urine. Having a weak urine stream. Other symptoms depend on the type of prostate problem you have and may include: Not being able to urinate at all. This is a medical emergency. Any problems, starting or controlling urine flow. Waking up often to urinate. Blood in your urine or urine that has an unusual smell or color. Fever, chills, or body aches. Great discomfort or pain: While urinating or after ejaculation. In your abdomen (belly), between your scrotum and anus, or in your scrotum or penis. Contact your provider if you have any of these symptoms. How are prostate diseases diagnosed? To find out if you have a prostate problem, your provider will: Ask about your medical history and symptoms. Ask about your family health history. Do a physical exam. The exam may include a digital rectal exam (DRE) of your prostate. In a DRE, your provider inserts a gloved finger into your rectum to feel the general size and condition of your prostate. Order tests, if needed. Tests may include: Blood and urine tests to look for infection. Urodynamic testing to see how well you can hold and release urine. Cystoscopy to look inside your urethra and bladder. Ultrasound pictures of your prostate and urinary tract. A PSA blood test (prostate-specific antigen test). Prostate biopsy to diagnose or rule out cancer. Treatment depends on what prostate disease you have and which symptoms bother you most. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary: Prostate Disease, also known as prostatic diseases, is related to prostatic hyperplasia, benign and prostate cancer, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Prostate Disease is PCA3 (Prostate Cancer Associated 3). The drugs Povidone-iodine and Iodine have been mentioned in the context of this disorder. Affiliated tissues include prostate, kidney and heart.

Related Diseases for Prostate Disease

Diseases related to Prostate Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 142)
# Related Disease Score Top Affiliating Genes
1 prostatic hyperplasia, benign 31.5 SERPINA3 PCA3 KLK3 FOLH1 AR
2 prostate cancer 31.2 TERC SERPINA3 SCHLAP1 PTENP1 PRNCR1 PCGEM1
3 prostatitis 30.9 PCA3 KLK3 AR
4 prostatic hypertrophy 30.7 SERPINA3 PCA3 KLK3 FOLH1 AR
5 osteogenic sarcoma 30.5 PCAT1 MEG3 MALAT1 H19 GAS5 CDKN2B-AS1
6 thyroid carcinoma 30.5 MALAT1 H19 GAS5 CDKN2B-AS1
7 nodular prostate 30.4 KLK3 FOLH1
8 hepatocellular carcinoma 30.4 TERC SERPINA3 PTENP1 PCAT1 MEG3 MALAT1
9 bladder cancer 30.4 TERC SCHLAP1 PCAT1 MEG3 MALAT1 KLK3
10 prostatic adenoma 30.3 SERPINA3 KLK3 CDKN2B-AS1 AR
11 suppression of tumorigenicity 12 30.3 SERPINA3 KLK3 FOLH1 AR
12 kidney cancer 30.3 MEG3 MALAT1 H19 GAS5 FOLH1
13 lipoprotein quantitative trait locus 30.3 SERPINA3 IGF2-AS H19 GAS5 CDKN2B-AS1
14 urethral stricture 30.2 KLK3 FOLH1
15 primary cutaneous amyloidosis 10.6 SERPINA3 PCA3 KLK3 FOLH1 AR
16 high grade glioma 10.6 PRNCR1 PCGEM1 MEG3 MALAT1 LINC00963 H19
17 glioma 10.6 MEG3 MALAT1 H19 GAS5 CDKN2B-AS1 CBR3-AS1
18 prostatic acinar adenocarcinoma 10.6 KLK3 FOLH1 AR
19 prostate small cell carcinoma 10.6 KLK3 FOLH1 AR
20 cervical cancer 10.5 TERC PCAT1 MEG3 MALAT1 H19 GAS5
21 prostate neuroendocrine neoplasm 10.5 KLK3 FOLH1 AR
22 castration-resistant prostate carcinoma 10.5 KLK3 FOLH1 AR
23 gastric cancer 10.5 TERC SERPINA3 PTENP1 PRNCR1 PCAT1 MEG3
24 male reproductive organ benign neoplasm 10.5 SERPINA3 KLK3 AR
25 lymph node carcinoma 10.5 KLK3 FOLH1 AR
26 prostate adenoid cystic carcinoma 10.5 KLK3 AR
27 renal cell carcinoma, nonpapillary 10.5 PTENP1 MEG3 MALAT1 LINC00963 H19 GAS5
28 ovarian epithelial cancer 10.5 MEG3 MALAT1 H19
29 squamous cell carcinoma 10.5 PCAT1 MALAT1 H19 CDKN2B-AS1 CBR3-AS1
30 ureter squamous cell carcinoma 10.5 KLK3 CDKN2B-AS1
31 esophagus squamous cell carcinoma 10.5 MEG3 MALAT1 GAS5
32 prostate leiomyoma 10.5 KLK3 AR
33 thyroid cancer, nonmedullary, 1 10.5 MEG3 MALAT1 H19
34 prostate calculus 10.5 KLK3 AR
35 osteoarthritis 10.5 PCGEM1 MEG3 H19 GAS5
36 male reproductive organ cancer 10.5 SERPINA3 KLK3 FOLH1 AR
37 male reproductive system disease 10.5 SERPINA3 KLK3 FOLH1 AR
38 nasopharyngeal carcinoma 10.5 MEG3 MALAT1 H19 GAS5 CDKN2B-AS1
39 myeloma, multiple 10.5 PCAT1 MEG3 MALAT1 H19 GAS5
40 lymphocele 10.5 KLK3 FOLH1
41 esophageal cancer 10.5 PCAT1 MEG3 MALAT1 H19 GAS5 CDKN2B-AS1
42 prostate stromal sarcoma 10.5 PCA3 KLK3
43 wilms tumor 1 10.5 SERPINA3 MEG3 IGF2-AS H19
44 liver cirrhosis 10.5 SERPINA3 MEG3 MALAT1 GAS5
45 gallbladder cancer 10.5 MEG3 MALAT1 H19 CDKN2B-AS1
46 germ cell cancer 10.5 SERPINA3 H19 AR
47 glioblastoma 10.5 PCAT1 MEG3 MALAT1 LINC00963 H19 GAS5
48 apocrine adenocarcinoma 10.5 SERPINA3 AR
49 aortic aneurysm, familial abdominal, 1 10.5 SERPINA3 H19 CDKN2B-AS1
50 bladder urothelial carcinoma 10.5 MEG3 MALAT1 GAS5

Comorbidity relations with Prostate Disease via Phenotypic Disease Network (PDN):


Prostate Cancer Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Prostate Disease:



Diseases related to Prostate Disease

Symptoms & Phenotypes for Prostate Disease

UMLS symptoms related to Prostate Disease:


tremor; angina pectoris; equilibration disorder; prostatism

Drugs & Therapeutics for Prostate Disease

Drugs for Prostate Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 44)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Povidone-iodine Approved Phase 4 25655-41-8
2
Iodine Approved, Investigational Phase 4 7553-56-2 807
3
Povidone K30 Approved, Experimental, Withdrawn Phase 4 9003-39-8 6917 131751496
4
Alfuzosin Approved, Investigational Phase 4 81403-80-7 2092
5
Cadexomer iodine Experimental Phase 4 94820-09-4
6 Anti-Infective Agents Phase 4
7 Anti-Infective Agents, Local Phase 4
8 Blood Substitutes Phase 4
9 Plasma Substitutes Phase 4
10 Adrenergic alpha-Antagonists Phase 4
11 Neurotransmitter Agents Phase 4
12 Adrenergic Antagonists Phase 4
13 Adrenergic alpha-1 Receptor Antagonists Phase 4
14 Adrenergic Agents Phase 4
15
Ethanol Approved Phase 1, Phase 2 64-17-5 702
16
Nivolumab Approved Phase 1, Phase 2 946414-94-4
17
Coal tar Approved Phase 1, Phase 2 8007-45-2
18
Ipilimumab Approved Phase 2 477202-00-9
19
Imatinib Mesylate Phase 2 220127-57-1
20 Protein Kinase Inhibitors Phase 2
21 Hormones Phase 1, Phase 2
22 Androgens Phase 1, Phase 2
23 Hormone Antagonists Phase 1, Phase 2
24 Immunoglobulins, Intravenous Phase 1, Phase 2
25 Immunoglobulins Phase 1, Phase 2
26 Immunoglobulin G Phase 1, Phase 2
27 Immune Checkpoint Inhibitors Phase 1, Phase 2
28 Antibodies, Monoclonal Phase 1, Phase 2
29 Antibodies Phase 1, Phase 2
30 Antineoplastic Agents, Immunological Phase 1, Phase 2
31
Gallium 68 PSMA-11 Phase 2 91800164
32 Taxane Phase 1, Phase 2 108169
33 177Lu-PSMA-617 Phase 2
34 Hops Approved
35
Finasteride Approved 98319-26-7 57363
36
Lidocaine Approved, Vet_approved 137-58-6 3676
37
Ceftriaxone Approved 73384-59-5 5479530
38 Anesthetics, Local
39 Estrogens
40 5-alpha Reductase Inhibitors
41 Anesthetics
42 Anti-Bacterial Agents
43 Antibiotics, Antitubercular
44 Radiopharmaceuticals

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 A Prospective Randomized Trial of Povidone-iodine Suppository Before Transrectal Ultrasound Guided Prostate Biopsy Unknown status NCT02245334 Phase 4 Povidone-Iodine
2 ALEX-XL: Alfuzosin XL-Lower Urinary Tract Symptoms Efficacy and Sexuality Study Completed NCT00575913 Phase 4 Alfuzosin
3 Evaluation of the Safety and Tolerability of Transurethral Alcohol Injection for the Treatment of BPH (Enlarged Prostate) Completed NCT00037141 Phase 1, Phase 2 dehydrated alcohol
4 An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy Completed NCT01316458 Phase 2 STI571 (Glivec®)
5 Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer Recruiting NCT03543189 Phase 1, Phase 2 Nivolumab;Androgen Deprivation Therapy
6 An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer Recruiting NCT05413850 Phase 1, Phase 2 177Lu-rhPSMA-10.1 injection
7 Phase II Study of Radionuclide 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With MetastaticCastration Resistant Prostate Cancer (mCRPC) Recruiting NCT05150236 Phase 2 177Lu-PSMA-617;Ipilimumab;Nivolumab
8 High-Resolution, 18F-PSMA PET-MRI for Mapping Prostate Cancer in Patients Considering Focal High-Intensity Focused Ultrasound (HIFU) Therapy or Radical Prostatectomy Recruiting NCT04461509 Phase 2 18F-PSMA
9 A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer Terminated NCT02606123 Phase 1, Phase 2 EPI-506
10 A Phase II Study of Ixabepilone Prior to Surgery for High-risk Localized Prostate Cancer Terminated NCT00672009 Phase 2 Ixabepilone
11 4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy Withdrawn NCT03658408 Phase 2 4-aminopyridine;placebo
12 Pilot Study to Evaluate In Vivo Plastic Scintillation Detectors for Real-Time Radiation Dosimetry During Prostate Cancer Radiotherapy Completed NCT01307852 Phase 1
13 A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) Active, not recruiting NCT04249947 Phase 1 Rimiducid
14 Ejaculation Preserving Photoselective Vaporization Versus Plasma Kinetic Vaporization Versus Transurethral Resection Of The Prostate For Management Of Benign Prostatic Enlargement: An Objective Evaluation Through a Prospective Randomized Trial Unknown status NCT03589196
15 MR/TRUS Fusion Guided Prostate Biopsy- An Improved Way To Detect And Quantify Prostate Cancer Unknown status NCT04026763
16 Hypnosis Mask: a New Approach to Management of Pain in Medical Imaging Unknown status NCT03711643
17 68Ga PSMA-11 in Patients With Intermediate to High-risk Prostate Cancer Before Prostatectomy or With Biochemical Recurrence of Prostate Cancer. Approved for marketing NCT04452136 68GA PSMA-HBED-CC
18 Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome Correlating Clinical Indicators Among Asian Adult Males With Elevated Prostate Specific Antigen (PSA) Completed NCT01826617
19 Intratesticular Hormone Levels in Healthy Young Men Completed NCT00756561
20 The Relationship Between Serum PSA Levels and WBC, Delta Neutrophil Index (DNI) and Other Hematological Parameters Completed NCT05399940
21 Prospective Evaluation of the Intraoperative Use of Translumenal Flexible Endoscopes During Combined Flexible and Laparoscopic Foregut and Urologic Surgery Completed NCT00484783
22 Randomized, Evaluator-blind, Controlled Trial to Evaluate the Efficacy and Safety of Prostatic Arterial Embolization Versus a Sham Procedure for Benign Prostatic Hyperplasia With Severe LUTS Not Adequately Controlled With Alpha-blockers Completed NCT02074644
23 Prostatic Artery Embolization for Obstructive Uropathy Due to Prostate Cancer Completed NCT03104907
24 Prostatic Artery Embolization for Benign Prostatic Obstruction Completed NCT03099421
25 Validation of a Semiquantitative Screening Assay for PSA Completed NCT00853710
26 Sexuality and Management of Benign Prostatic Hyperplasia With Alfuzosin Completed NCT00941343 Alfuzosin (XATRAL® - SL770499)
27 A Prospective Randomized Study Whether Low-energy Extracorporeal Shockwave Therapy (LI-ESWT) Can Increase Erectile Function in Patients After Radical Prostatectomy Completed NCT03192917
28 Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment . Geriatric Oncology Protocol in Aquitaine Country. Completed NCT00210249
29 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy Recruiting NCT04288427 Finasteride
30 MR/TRUS Fusion Guided Prostate Biopsy - An Improved Way to Detect and Quantify Prostate Cancer Recruiting NCT04599218
31 A Study to Evaluate the Safety and Efficacy of Focal US Guided Cryo-ablation Using DynaCAD / UroNAV Preplanning / Guidance of Locally Confined Low to Intermediate Risk Prostate Cancer Recruiting NCT04656678
32 Culturally Adapted Cognitive Behavioral Stress and Self-Management (C-CBSM) Intervention for Prostate Cancer Recruiting NCT03344757
33 Soractelite(Tm) Transperineal Laser Ablation for Benign Prostatic Hyperplasia With Bladder Outlet Obstruction Recruiting NCT04760483
34 Feasibility and Safety of Transurethral HIFU in Various Prostate Diseases; Particularly Prostate Cancer Recruiting NCT03350529
35 Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed Recruiting NCT04462926
36 Prospective Cohort Study With Collection of Clinical Data, Serum and Plasma of Patients With Prostate Disease Active, not recruiting NCT04024475
37 MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness Active, not recruiting NCT01464216
38 Molecular Studies and Clinical Correlations in Human Prostatic Disease Active, not recruiting NCT00578240
39 Evaluation of the in Vivo Biodistribution and Radiation Dosimetry of 68Ga-HTK03149 for Use as a Diagnostic Radiopharmaceutical Active, not recruiting NCT04831307
40 Cryoablation: An Observational Study of Hemi-Gland Cryoablation Outcomes for Prostate Cancer at University of California at Los Angeles (UCLA) Enrolling by invitation NCT03503643
41 Evaluation of a Soft Tissue Biopsy System for Trans-rectal and Trans-perineal Biopsy of the Prostate Not yet recruiting NCT05470127
42 Evaluating the Role of Biparametric MRI and Image-fusion Targeted Biopsies for Detection of Prostate Cancer Not yet recruiting NCT05574647
43 A Questionnaire Study by Elevated Prostate Specific Antigen (PSA): Do Men Where Subsequent Assessment Shows Prostate Cancer, Higher Levels of Neuroticism and Stress Compared to Those Who do Not Get the Diagnosis? Terminated NCT02031029
44 Effect of Laser Settings on Postoperative Voiding Symptoms in Patients Undergoing Holmium Laser Enucleation of the Prostate: A Randomized Prospective Trial Withdrawn NCT04699552
45 ConfirmMDx Assay is Multiparametric MRI (mpMRI) PIRADS Scored Lesions After a Negative MR/US Fusion Biopsy Withdrawn NCT03597386

Search NIH Clinical Center for Prostate Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Mannitol hexanitrate

Cochrane evidence based reviews: prostatic diseases

Genetic Tests for Prostate Disease

Anatomical Context for Prostate Disease

Organs/tissues related to Prostate Disease:

MalaCards : Prostate, Kidney, Heart, Salivary Gland, Neutrophil, Smooth Muscle, Spinal Cord

Publications for Prostate Disease

Articles related to Prostate Disease:

(show top 50) (show all 1344)
# Title Authors PMID Year
1
The use of 3D digital anatomy model improves the communication with patients presenting with prostate disease: The first experience in Senegal. 62 41
36454858 2022
2
Discovery proteomics defines androgen-regulated glycoprotein networks in prostate cancer cells, as well as putative biomarkers of prostatic diseases. 41
34782677 2021
3
Localization of external urethral orifice in coronary sulcus during urethroplasty in case of severe hypospadias accompanied by prostatic utricle cyst. 41
34736451 2021
4
Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. 53 62
19128049 2009
5
Serum prostate-specific antigen levels in Middle Eastern men with subclinical prostatitis. 53 62
17159365 2007
6
Effect of two years of growth hormone and insulin-like growth factor-I suppression on prostate diseases in acromegalic patients. 53 62
11061535 2000
7
Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. 53 62
10632336 1999
8
An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. 53 62
9730460 1998
9
Prostate-specific antigen and its complexes with alpha 1-antichymotrypsin in the plasma of patients with prostatic disease. 53 62
8977078 1996
10
Prostate-specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease. 53 62
8750649 1995
11
[Examination of serum prostate specific antigen (PSA) in the mass screening for prostatic diseases]. 53 62
7685140 1993
12
Lipidic extract of whole tomato reduces hyperplasia, oxidative stress and inflammation on testosterone-induced BPH in obese rats. 62
36464759 2022
13
Glyphosate disturbs various epigenetic processes in vitro and in vivo - A mini review. 62
36030868 2022
14
What We Have Learned from The Testosterone Trials. 62
36309420 2022
15
The effect of race on treatment patterns and subsequent health-related quality of life outcomes in men undergoing treatment for localized prostate cancer. 62
36357592 2022
16
Single-cell transcriptomics reveals cell type diversity of human prostate. 62
35395421 2022
17
Single-cell atlas of epithelial and stromal cell heterogeneity by lobe and strain in the mouse prostate. 62
36373171 2022
18
Race-specific prostate cancer outcomes in a cohort of military health care beneficiaries undergoing surgery: 1990-2017. 62
35638719 2022
19
18 F-DCFPyL positron emission tomography/magnetic resonance imaging-guided ultrasound fusion biopsy is an identical pathway in prostate cancer diagnosis. 62
36281654 2022
20
Assessment of the possibility of using biomarkers (CCL11 and TGF-beta 1) in the diagnosis of prostate gland hyperplasia in dogs. 62
36030614 2022
21
Single-cell RNA-sequencing technology demonstrates the heterogeneity between aged prostate peripheral and transitional zone. 62
36245324 2022
22
Impact of chronic exposure of rats to bisphenol A from perinatal period to adulthood on intraprostatic levels of 5α-reductase isozymes, aromatase, and genes implicated in prostate cancer development. 62
35378123 2022
23
Race and Ethnicity Have a Significant Effect on the Disclosure of Erectile Function: An Analysis of NHANES Response Patterns. 62
35680045 2022
24
Brazilian Berry Extract Differentially Induces Inflammatory and Immune Responses in Androgen Dependent and Independent Prostate Cancer Cells. 62
36258714 2022
25
Development and validation of 68Ga-PSMA-11 PET/CT-based radiomics model to detect primary prostate cancer. 62
36175753 2022
26
Erectile dysfunction and prostate diseases are the predominant Google search terms amongst men's health topics. 62
34017114 2022
27
Prostate Infiltration by Treg and Th17 Cells as an Immune Response to Propionibacterium acnes Infection in the Course of Benign Prostatic Hyperplasia and Prostate Cancer. 62
36012113 2022
28
Ameliorative effect of Abeliophyllum distichum Nakai on benign prostatic hyperplasia in vitro and in vivo. 62
35919286 2022
29
Automatic Segmentation of Prostate MRI Based on 3D Pyramid Pooling Unet. 62
35923153 2022
30
The combination of highly efficient resonance energy transfer in one nanocomposite and ferrocene-quenching for ultrasensitive electrochemiluminescence bioanalysis. 62
35550937 2022
31
Identification of novel serological autoantibodies in Chinese prostate cancer patients using high-throughput protein arrays. 62
35831618 2022
32
Naftopidil enantiomers suppress androgen accumulation and induce cell apoptosis via the UDP-glucuronosyltransferase 2B15 in benign prostate hyperplasia. 62
35504423 2022
33
Assessment of elastographic Q-analysis score combined with Prostate Imaging-Reporting and Data System (PI-RADS) based on transrectal ultrasound (TRUS)/multi-parameter magnetic resonance imaging (MP-MRI) fusion-guided biopsy in differentiating benign and malignant prostate. 62
35782253 2022
34
Choosing appropriate patient-reported outcome measures for prostate disease. 62
35783591 2022
35
Multi-scale discriminative network for prostate cancer lesion segmentation in multiparametric MR images. 62
35851482 2022
36
Standard-free single magnetic bead evaluation: a stable nanoplatform for prostate disease differentiation. 62
35733887 2022
37
The Role of Heat Shock Protein 70 Subfamily in the Hyperplastic Prostate: From Molecular Mechanisms to Therapeutic Opportunities. 62
35805135 2022
38
Prostate diseases and microbiome in the prostate, gut, and urine. 62
35510078 2022
39
Influence of Trichomonas vaginalis macrophage migration inhibitory factor on the proliferation activity of prostate epithelial cell line and its preliminary mechanism. 62
35191055 2022
40
Prospective quality of life in men choosing open vs. robotic radical prostatectomy: long-term results from a racially diverse multi-institutional database. 62
35279731 2022
41
Prostate organogenesis. 62
35726824 2022
42
Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer: A Systematic Review. 62
35029127 2022
43
Race-specific prostate cancer outcomes in a cohort of low and favorable-intermediate risk patients who underwent external beam radiation therapy from 1990 to 2017. 62
35616266 2022
44
Novel role of prostate cancer risk variant rs7247241 on PPP1R14A isoform transition through allelic TF binding and CpG methylation. 62
34849858 2022
45
Impact of Age and Race on Health-Related Quality of Life Outcomes in Patients Undergoing Radical Prostatectomy for Localized Prostate Cancer. 62
34428537 2022
46
Diagnostic Value of microRNA-375 as Future Biomarker for Prostate Cancer Detection: A Meta-Analysis. 62
35454368 2022
47
[The value of relaxation time quantitative technique from synthetic magnetic resonance imaging in the diagnosis and invasion assessment of prostate cancer]. 62
35436808 2022
48
Machine learning-based prediction of invisible intraprostatic prostate cancer lesions on 68 Ga-PSMA-11 PET/CT in patients with primary prostate cancer. 62
34845536 2022
49
68Ga-PSMA-11 PET Identified Tumor Recurrence in Prostatectomy Bed With Rising PSA of 0.9 ng/mL but Negative on MRI and 18F-Fluciclovine PET Scan. 62
35020642 2022
50
Clinical application of free/total PSA ratio in the diagnosis of prostate cancer in men over 50 years of age with total PSA levels of 2.0-25.0 ng ml-1 in Western China. 62
34916475 2022

Variations for Prostate Disease

Expression for Prostate Disease

Search GEO for disease gene expression data for Prostate Disease.

Pathways for Prostate Disease

GO Terms for Prostate Disease

Biological processes related to Prostate Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of systemic arterial blood pressure GO:0003073 8.92 KLK3 AR

Sources for Prostate Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....